喘可治注射液治疗慢性阻塞性肺疾病急性加重期的系统评价(1)
[摘要]計算机检索PubMed，CNKI等7个中英文数据库，查找有关喘可治注射液治疗慢性阻塞性肺疾病急性加重期的随机对照试验(RCT)，检索时限为建库至2016年11月。由2位研究者按纳入标准独立筛选文献、提取资料，并用Cochrane手册针对RCT的偏倚风险评价工具评价文献质量后，采用RevMan 53软件进行Meta分析，系统评价喘可治注射液治疗慢性阻塞性肺疾病急性加重期的炎症因子及肺功能改善情况、疗效及安全性。共纳入13篇RCT，包括1 016例患者。Meta分析结果显示：与对照组比较，喘可治组临床有效率更高[RR=115，95% CI(106，123)，P=0000 3]；肺功能改善更明显，包括第1秒呼气量(FEV1) [MD=021，95% CI(015，027)，P<0000 01]、用力肺活量(FVC) [MD=036，95% CI(015，056)，P=0000 6]和第1秒呼吸容积占用力肺活量百分比(FEV1/FVC) [MD=685，95% CI(468，902)，P<0000 01]；并且降低炎症因子水平，包括白细胞介素6(IL6)[MD=-635，95% CI (-823，-447)，P<0000 01]、白细胞介素8(IL8)[MD=-200，95% CI (-313，087)，P=0000 5]和肿瘤坏死因子α(TNFα)[MD=-279，95% CI (-461，-097)，P=0003]。除此之外，喘可治组不良反应发生率低，且无严重不良反应事件。研究表明，在常规对症治疗基础上加喘可治注射液治疗慢性阻塞性肺疾病急性加重期，可提高临床疗效，改善肺功能，有助于减少炎症发生，安全性好，但受纳入研究数量及质量的限制，尚需要更多高质量RCT进一步验证。
, 百拇医药
[关键词]喘可治注射液； 慢性阻塞性肺疾病； 急性加重期； 炎症因子； 系统评价
[Abstract]To evaluate the inflammatory factors， the pulmonary function， the efficiency and the safety of Chuankezhi injection for treating acute exacerbation of chronic obstructive pulmonary disease (AECOPD) The randomized controlled trials (RCTs) on Chuankezhi injection for treating AECOPD were collected from 7 databases (PubMed， CNKI， et al) between inception to November 2016 Two reviewers independently screened literature and extracted the data according to the inclusion and exclusion criteria， and assessed methodological quality of included studies according to the criteria from Cochrane Reviewer′s Handbook 53 Then， Metaanalysis was conducted by using RevMan 53 software A total of 13 RCTs involving 1 016 patients were included Metaanalysis results indicated that Chuankezhi group was superior to the control group in the clinical effectiveness [RR=115， 95% CI(106， 123)， P=0000 3]， improved pulmonary functions including forced expiratory volume in one second (FEV1) [MD=021， 95% CI (015， 027)， P<0000 01]， forced vital capacity (FVC) [MD=036， 95% CI(015， 056)， P=0000 6]， the first seconds breathing volume percentage of forced vital capacity (FEV1/FVC) [MD=685， 95% CI(468， 902)， P<0000 01] and decreased the level of inflammatory factors including interleukin6 (IL6) [MD=-635， 95% CI (-823， -447)， P<0000 01]， IL8 [MD = -200， 95% CI ( -313， 087)， P=0000 5]， tumor necrosis factorα (TNFα) [ MD=-279， 95% CI (-461，-097)， P=0003] Besides， there were no frequently happened or serious adverse reactions observed in Chuankezhi group The results showed that Chuankezhi injection could improve the efficiency and the pulmonary function， reduce inflammation for AECOPD with a high safety on the basis of routine symptomatic treatment However， due to limited quantity and quality of the included studies， the conclusion above should be further verified by conducting more high quality RCTs, 百拇医药(陈诗琪 杨欣宇 唐潇旖 李敏 刘硕 梁婧 张晓雨 商洪才)
, 百拇医药
[关键词]喘可治注射液； 慢性阻塞性肺疾病； 急性加重期； 炎症因子； 系统评价
[Abstract]To evaluate the inflammatory factors， the pulmonary function， the efficiency and the safety of Chuankezhi injection for treating acute exacerbation of chronic obstructive pulmonary disease (AECOPD) The randomized controlled trials (RCTs) on Chuankezhi injection for treating AECOPD were collected from 7 databases (PubMed， CNKI， et al) between inception to November 2016 Two reviewers independently screened literature and extracted the data according to the inclusion and exclusion criteria， and assessed methodological quality of included studies according to the criteria from Cochrane Reviewer′s Handbook 53 Then， Metaanalysis was conducted by using RevMan 53 software A total of 13 RCTs involving 1 016 patients were included Metaanalysis results indicated that Chuankezhi group was superior to the control group in the clinical effectiveness [RR=115， 95% CI(106， 123)， P=0000 3]， improved pulmonary functions including forced expiratory volume in one second (FEV1) [MD=021， 95% CI (015， 027)， P<0000 01]， forced vital capacity (FVC) [MD=036， 95% CI(015， 056)， P=0000 6]， the first seconds breathing volume percentage of forced vital capacity (FEV1/FVC) [MD=685， 95% CI(468， 902)， P<0000 01] and decreased the level of inflammatory factors including interleukin6 (IL6) [MD=-635， 95% CI (-823， -447)， P<0000 01]， IL8 [MD = -200， 95% CI ( -313， 087)， P=0000 5]， tumor necrosis factorα (TNFα) [ MD=-279， 95% CI (-461，-097)， P=0003] Besides， there were no frequently happened or serious adverse reactions observed in Chuankezhi group The results showed that Chuankezhi injection could improve the efficiency and the pulmonary function， reduce inflammation for AECOPD with a high safety on the basis of routine symptomatic treatment However， due to limited quantity and quality of the included studies， the conclusion above should be further verified by conducting more high quality RCTs, 百拇医药(陈诗琪 杨欣宇 唐潇旖 李敏 刘硕 梁婧 张晓雨 商洪才)